NCT04988022View on ClinicalTrials.gov

Dupilumab in the Treatment of Keloids

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

March 24, 2025

Study Completion Date

March 24, 2025

Conditions
Keloid
Interventions
DRUG

Dupilumab

300 mg prefilled syringe

DRUG

Placebo

Matching placebo

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER